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Abstract
Background—Recent antimicrobial resistance data are lacking from inpatient oncology settings 
to guide infection prophylaxis and treatment recommendations. We describe central line-
associated bloodstream infection (CLABSI) pathogens and antimicrobial resistance patterns 
reported from oncology locations to the CDC’s National Healthcare Safety Network (NHSN).
Methods—CLABSI data reported to NHSN from 2009–2012 from adult inpatient oncology 
locations were compared to data from non-oncology adult locations within the same hospitals. 
Pathogen profile, antimicrobial resistance rates, and CLABSI incidence rates/per 1000 central line-
days were calculated. CLABSI incidence rates were compared using Poisson regression.
Results—During 2009–2012, 4654 CLABSIs were reported to NHSN from 299 adult oncology 
units. The most common organisms causing CLABSI in oncology locations were coagulase-
negative staphylococci (16.9%), Escherichia coli (11.8%), and Enterococcus faecium (11.4%). 
Fluoroquinolone resistance was more common among E. coli CLABSI in oncology than non-
oncology locations (56.5% vs 41.5% of isolates tested, P<0.0001) and increased significantly from 
2009–2010 to 2011–2012 (49.5% vs 60.4%, P=0.01). Furthermore, rates of CLABSI were 
significantly higher in oncology compared to non-oncology locations for fluoroquinolone-resistant 
E. coli (rate ratio: 7.37, 95% confidence interval, 6.20–8.76) and vancomycin-resistant E. faecium 
(rate ratio: 2.27, 95% confidence interval, 2.03–2.53). However, resistance rates for some 
organisms, such as Klebsiella spp. and Pseudomonas aeruginosa, were lower in oncology than in 
non-oncology locations.
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Conclusions—Antimicrobial-resistant E. coli and E. faecium have become significant 
pathogens in oncology. Practices for antimicrobial prophylaxis and empiric antimicrobial therapy 
should be regularly assessed in conjunction with contemporary antimicrobial resistance data.
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Background
Bloodstream infections, estimated to occur in 10–25% of oncology patients, are a substantial 
cause of serious morbidity in this patient population [1]. Neutropenia and gastrointestinal 
mucosal damage resulting from cytotoxic cancer therapies, as well as the frequent use of 
central venous catheters, are significant risk factors for bloodstream infections originating 
from endogenous colonic and/or skin flora [2,3]. Preventing bloodstream infections and 
associated complications is therefore a critical patient safety issue and has motivated the 
creation of clinical practice guidelines for antibiotic prophylaxis and empiric treatment of 
neutropenic cancer patients with fever [1].
These guidelines refer to nationwide epidemiologic data to direct specific antimicrobial 
regimens towards the most common pathogens isolates from in oncology patients [1,4]. 
However, the referenced data are from over 15 years ago, and there has since been no other 
large-scale survey of cancer-associated bloodstream infections in the United States. [4]. In 
the last 10–15 years, the landscape of antimicrobial resistance has changed substantially for 
all patient care in the United States. Methicillin-resistant Staphylococcus aureus emerged as 
a significant pathogen in the community; and resistant gram-negative organisms, including 
extended spectrum β-lactamase- (ESBL) producing, carbapenem-resistant and 
fluoroquinolone-resistant Enterobacteriaceae are increasingly viewed as major threats [5–9].
In addition to these overall trends in antimicrobial resistance, oncology patient populations 
might be uniquely and more severely affected by emerging antimicrobial-resistant threats. 
For example, although prophylactic use of fluoroquinolones in high-risk neutropenic 
patients has been reported to decrease bloodstream infections [10], hospitalizations [11], and 
mortality [12], and has been recommended in professional society guidelines [1,13], 
significant concerns have been raised about selection of antimicrobial-resistant organisms in 
conjunction with this practice [14,15]. Reports from single centers have reported increases in 
resistance among gram-negative pathogens associated with fluoroquinolone prophylaxis 
[16–18], but it is unknown how widespread fluoroquinolone resistance is across oncology 
inpatient care settings or whether emerging resistance patterns observed in oncology units 
differ from those in other hospital locations in the United States.
We analyzed data reported from oncology patient care locations in short-stay acute care 
hospitals to the Centers for Disease Control and Prevention’s National Healthcare Safety 
Network (NHSN) to describe recent epidemiology of pathogens causing bloodstream 
infections and associated antimicrobial resistance.
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Methods
NHSN receives healthcare-associated infection reports from healthcare facilities in the 
United States and has been described previously [19]. During the time period these data 
were reported, an infection was considered healthcare-associated for reporting purposes if 
there was no evidence that it was present or incubating at the time of admission. 
Bloodstream infections were defined by either (1) a positive blood culture growing a 
recognized pathogen (e.g., Staphylococcus aureus, Escherichia coli); or (2) at least two 
positive cultures (from separate blood draws collected no more than 2 days apart) growing a 
common commensal organism (e.g., coagulase-negative staphylococci, viridans group 
streptococci) with signs/symptoms consistent with a bloodstream infection: fever, chills or 
hypotension (any patient); or hypothermia, apnea, or bradycardia (infants only). Primary 
bloodstream infections are bloodstream infection events without another primary source of 
infection (as defined by NHSN criteria). Central line-associated bloodstream infections 
(CLABSIs) were primary bloodstream infections occurring in patients with central line in 
place at the time of infection or removed within the 48 hours before, without a minimum 
duration that the central line had to have been in place.
Hospitals reporting CLABSI data submit the date of the CLABSI event, type of inpatient 
unit in which the event occurred, up to three organisms associated with the CLABSI, and 
results of antimicrobial susceptibility testing performed by the hospital laboratory. For 
inpatient units where CLABSI surveillance is being performed, hospitals also report 
monthly the total number of inpatient-days in the unit and the number of inpatient-days for 
which a patient had at least one central line in place (central line-days) [20]. In oncology 
units only, central line-days can be reported as temporary vs permanent central line-days. To 
facilitate comparisons between oncology and other units, in this analysis temporary and 
permanent central line-days were pooled together.
We analyzed all 2009–2012 NHSN CLABSI data reported from adult inpatient units of 
acute care hospitals. NHSN locations are classified by hospital staff as an oncology location 
type if the description matches at least 80% of a typical patient population in that location 
[21]. In 2013, NHSN oncology location types were categorized as oncology critical care, 
oncology step-down, hematology/oncology ward, hematopoietic stem cell transplant ward, 
leukemia ward, leukemia/lymphoma ward, and solid tumor ward locations, and these labels 
were also retrospectively applied to data previously reported to NHSN; we refer to these 
location types together as “oncology” in this analysis. To provide context for our results, we 
compared CLABSI data from oncology units to CLABSI data from non-oncology inpatient 
units (i.e., wards, critical care units, and step-down units) within facilities that reported 
CLABSI data from at least one oncology location during 2009–2012. Frequency of 
organisms causing CLABSI, patterns of antimicrobial resistance among those organisms, 
and CLABSI incidence rates were analyzed.
Antimicrobial resistance patterns among CLABSI were analyzed using published interim 
standard definitions [19,22]. Resistance to extended-spectrum cephalosporins was defined as 
nonsusceptibility (i.e., testing intermediate or resistant) to ceftazidime, cefepime, 
ceftriaxone, or cefotaxime (Enterobacteriaceae) or to ceftazidime or cefepime (Pseudomonas 
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aeruginosa). Fluoroquinolone resistance was defined as nonsusceptibility to ciprofloxacin or 
levofloxacin (P. aeruginosa) or to ciprofloxacin, levofloxacin, or moxifloxacin 
(Enterobacteriaceae). Aminoglycoside resistance was defined as nonsusceptibility to 
amikacin, gentamicin, or tobramycin. In this analysis, carbapenem resistance was defined as 
nonsusceptibility to imipenem, meropenem, or doripenem. For P. aeruginosa isolates, 
multidrug resistance was defined as nonsusceptibility to at least one drug in three of the five 
following antimicrobial groups: piperacillin or piperacillin/tazobactam, extended-spectrum 
cephalosporins (cefepime or ceftazidime), fluoroquinolones (ciprofloxacin or levofloxacin), 
aminoglycosides, and carbapenems. For Enterobacteriaceae, multidrug resistance was 
defined as nonsusceptibility to at least one drug in three of the five following groups: 
piperacillin or piperacillin/tazobactam, extended-spectrum cephalosporins (ceftazidime, 
cefepime, ceftriaxone, or cefotaxime), fluoroquinolones (ciprofloxacin, levofloxacin, or 
moxifloxacin), aminoglycosides, and carbapenems.
Statistical analyses were performed with SAS software version 9.3 (SAS Institute Inc., Cary, 
NC). Proportions were compared with χ2 or Fisher’s exact tests. Incidence rates of CLABSI 
per 1000 central-line days were calculated as (number of CLABSI)/(number of central line-
days) × 1000. For some CLABSI, antimicrobial susceptibility results were not available for 
every pathogen/antimicrobial combination of interest. Accordingly, to calculate CLABSI 
incidence rates for specific antimicrobial-resistant pathogens, for each CLABSI pathogen of 
interest we multiplied the proportion resistant out of those tested (i.e., data available in 
NHSN) by the total number of CLABSI associated with that pathogen (including those 
without available antimicrobial susceptibility results) to generate an estimate for number of 
CLABSI due to the resistant organism. CLABSI incidence rate ratios and rate differences 
were assessed using Poisson regression. Statistical significance was determined at a P value 
of ≤0.05.
Results
General description
During 2009–2012, 183 hospitals reported 4654 CLABSIs to NHSN from 299 adult 
oncology units over 3,843,442 inpatient-days. The extent of CLABSI reporting increased 
from 90 oncology locations providing data in 2009 to 256 locations in 2012. Most hospitals 
submitting oncology CLABSIs data (94.0%) were general acute care hospitals (Table 1); 
246 (82.3%) of the oncology locations reported at least 12 months of CLABSI data. Among 
CLABSIs reported from adult inpatient oncology locations, almost all occurred in either 
general hematology/oncology (55.7% of CLABSI) or hematopoietic stem cell transplant 
wards (40.3% of CLABSI).
Pathogens causing CLABSIs
Of CLABSIs reported from oncology locations, 4191 (90.1%) were monomicrobial (57.5% 
gram-positive, 35.1% gram-negative, 7.0% fungal, and 0.4% other). Candida spp. caused 
most fungal CLABSIs (90.8%).
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From both oncology and non-oncology locations, coagulase-negative staphylococci were the 
most common CLABSI organisms reported (Table 2). However, the organism profile of 
CLABSIs from oncology locations differed from non-oncology locations in other respects. 
For example, coagulase-negative staphylococci, S. aureus, non-albicans Candida spp., and 
Enterococcus faecalis, the four most common organisms from non-oncology locations, 
comprised only 35% of organisms from oncology locations but 47% of organisms from non-
oncology locations (P<0.0001). In contrast, Escherichia coli, E. faecium, and viridans group 
streptococci accounted for 29% of organisms from oncology locations but only 12% of 
organisms from non-oncology locations (P<0.0001).
Antimicrobial resistance
Aggregated across 2009–2012, antimicrobial susceptibility testing results were available for 
>70% of CLABSIs for most pathogen/resistance class combinations assessed (Table 3). In 
oncology locations, the highest overall prevalence of antimicrobial resistance were found in 
E. faecium (82.5% vancomycin-resistant), E. coli (56.5% fluoroquinolone-resistant), and S. 
aureus (45.6% methicillin-resistant). Carbapenem resistance was uncommon among E. coli 
and Klebsiella spp. (0.4% and 4.6%, respectively). Only 28.9% of viridans group 
streptococci had susceptibility information reported for penicillin. Of these, 62.6% were 
reported susceptible, 28.1% intermediate, and 9.3% resistant.
Compared to non-oncology locations, some organisms implicated in CLABSIs demonstrated 
increased resistance, some less resistance, and others similar levels of resistance in oncology 
(Table 3). For example, resistance for E. faecium was similarly high between oncology and 
non-oncology, whereas fluoroquinolone resistance and multidrug resistance in E. coli were 
more common in oncology. In contrast, resistance in S. aureus, Klebsiella spp. and P. 
aeruginosa was lower in oncology locations compared to non-oncology locations.
The highest incidence of CLABSIs from drug-resistant organisms in oncology occurred for 
vancomycin-resistant E. faecium (0.22 CLABSI/1000 central line-days), fluoroquinolone-
resistant E. coli (0.16 CLABSI/1000 central line-days), and methicillin-resistant S. aureus 
(0.11 CLABSI/1000 central line-days) (Figure 1). Incidence was significantly higher in 
oncology than in non-oncology locations for vancomycin-resistant E. faecium (rate ratio: 
2.27, 95% confidence interval, 2.03–2.53) and fluoroquinolone-resistant E. coli CLABSIs 
(rate ratio: 7.37, 95% confidence interval, 6.20–8.76) but not for methicillin-resistant S. 
aureus CLABSI (rate ratio: 1.08, 95% confidence interval, 0.94–1.24). The combined pooled 
mean CLABSI rate due to the resistant pathogens in Figure 1 was higher in oncology than 
outside oncology (rate difference: 0.29/1000 central line-days, 95% confidence interval, 
0.26–0.32/1000 central line-days). Almost all (89.1%) of the difference could explained by 
resistant E. coli and E. faecium.
Among most of the major CLABSI pathogens in oncology locations, resistance did not 
change significantly over time. The only pathogen with a significant temporal resistance 
trend was E. coli, for which the percentage resistant to fluoroquinolones increased from 
49.5% in 2009–2010 to 60.4% in 2011–2012 (P=0.01, data not shown).
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Discussion
This is the first nationwide evaluation of pathogen patterns and antimicrobial trends among 
bloodstream infections from a hospitalized oncology patient population in over a decade. 
Our analysis shows that fluoroquinolone-resistant E. coli and vancomycin-resistant E. 
faecium are common antimicrobial-resistant pathogens in adult inpatient oncology locations, 
particularly when compared to non-oncology locations. Furthermore, fluoroquinolone 
resistance in E. coli has increased significantly during recent years in oncology settings. 
These findings are of concern given that fluoroquinolone-resistant E. coli infections are 
associated with increased mortality in oncology patients [23]. Indeed, the impact of growing 
antimicrobial resistance in oncology has been highlighted recently [24]. Contemporary data 
regarding the prevalence of resistant pathogens could better define this impact moving 
forward.
We do not have data on the use of fluoroquinolone prophylaxis in oncology units reporting 
CLABSI data to NHSN, but use of specific antimicrobials in the care of oncology patients 
could contribute substantially to the resistance patterns we report here. Our results are 
consistent with reports from single-center studies describing increases in fluoroquinolone-
resistant organisms with adoption of fluoroquinolone prophylaxis. Given that 
fluoroquinolone use has also been associated with vancomycin-resistant Enterococcus 
colonization and infection [25–27], fluoroquinolone prophylaxis might also be contributing 
to the prominence of ancomycin-resistant enterococci as CLABSI pathogens in oncology 
patients. In reports of the initial studies demonstrating benefits for fluoroquinolone 
prophylaxis, investigators also cautioned that continued monitoring for development of 
resistant organisms was needed [10–12]. However, it is unknown what level of resistance 
would nullify the benefits of prophylaxis. This will need clarification in the near future if 
current trends continue. Indeed, some centers have elected to discontinue broad 
fluoroquinolone prophylaxis due to rising rates of resistance in E. coli isolates, the most 
common gram negative pathogen causing bloodstream infections in cancer patients (A. 
Freifeld, personal communication). Recent studies have also suggested that vancomycin is 
overused in oncology patients, which might additionally contribute to the high incidence 
rates of vancomycin-resistant E. faecium in oncology settings [28,29]. Another possible 
contributing factor is that oncology patients tend to be exposed to multiple and sometimes 
lengthy courses of antibiotic therapy, which may subsequently select for resistant pathogens. 
For instance, certain cephalosporins and anti-anaerobic drugs have also been described to 
promote overgrowth of vancomycin-resistant Enterococci in the lower intestine [30,31].
The increased frequency of some organisms among patients with bloodstream infections in 
oncology locations compared to non-oncology locations may also stem in part from 
mucositis-related bloodstream infections. For example, in some cases E. coli and viridans 
group streptococci may be related to mucositis and gastrointestinal mucosal barrier injury 
from cytotoxic chemotherapy rather than central lines [32]. In 2013 NHSN introduced a 
subcategory of bloodstream infections called mucosal barrier injury laboratory-confirmed 
bloodstream infections to help identify bloodstream infections with a high likelihood of 
being related to these non-central line-related factors [33]; however, that classification did 
not exist at the time these surveillance data were reported.
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Our results differ in several important ways from the findings reported in a widely-
referenced multicenter study of healthcare-associated bloodstream infections among 
oncology patients from 1995–2001 [4]. For example, viridans group streptococci, E. 
faecium, and E. coli were more common pathogens in our data than in the older report. In 
addition, Wisplinghoff and colleagues reported lower resistance for most major CLABSI 
pathogens, including S. aureus (29% vs 46% methicillin-resistant in our analysis), E. 
faecium (56% vs 83% vancomycin-resistant), Klebsiella spp. (1% vs 5% carbapenem 
resistant), and P. aeruginosa (6% vs 20% carbapenem-resistant). Fungal pathogens were 
somewhat less commonly identified in our report (9.3% vs 7.0%), which is likely due to the 
use of antifungal prophylaxis in certain populations. Notably, many of the pathogens that 
appear more prominent in our analysis of 2009–2012 data are those with the highest levels 
of resistance (e.g., E. faecium, E. coli). This finding is consistent with the notion that a broad 
change in environmental pressure, such as widespread fluoroquinolone prophylaxis within 
the oncology population, has yielded a profile of more resistant pathogens than that reported 
by Wisplinghoff et al. Changes in oncology treatment may have also contributed to 
differences seen. Methodological differences may account for some of the discrepancies in 
the results of the two analyses. For example, our analysis only included central line-
associated primary bloodstream infections, whereas Wisplinghoff et al. reported on all 
nosocomial primary and secondary bloodstream infections. Notwithstanding these 
differences, comparisons of the two analyses suggest that and resistant organisms selected 
by antimicrobial therapy and prophylaxis are increasingly causing infections in oncology 
patients.
However, we also found selected instances in which antimicrobial resistance was similar or 
even lower in oncology locations as compared to non-oncology locations, notably 
methicillin resistance in S. aureus and multiple resistance phenotypes in Klebsiella spp. and 
P. aeruginosa (Table 4). These findings may seem surprising in the context of intensive 
antimicrobial use for oncology patients, as described above. However, they are consistent 
with the following observations. First, different antimicrobial-resistant pathogens appear to 
flourish in particular settings, possibly related to differences in sources or mechanisms of 
acquisition among patients in those settings. For example, ESBL-producing E. coli have 
been described to be more predominant in strains circulating in the community, whereas 
ESBL Klebsiella spp. may be more typically related to transmission in hospitals [34–36]. 
Second, since many oncology patients are highly immunosuppressed, healthcare personnel 
caring for these patients might have heightened attention to proper infection control 
practices, which could result in reduced transmission of antimicrobial-resistant organisms. 
Furthermore, we found the incidence rates of CLABSI due to the antimicrobial-resistant 
organisms shown in Figure 1 to be higher in oncology than non-oncology settings. 
Therefore, although the prevalence of antimicrobial resistance among certain specific 
organisms may be higher in non-oncology settings, these data demonstrate that the 
occurrence of infections due to resistant organisms is higher in oncology.
We acknowledge limitations with this analysis. First, patient-level risk factor data for 
CLABSIs, such as malignancy type or neutropenia, are not reported to NHSN, and we were 
only able to analyze data at the level of hospital locations instead of at the individual patient 
level. For example, because of the way in which location codes are assigned for NHSN 
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reporting, it is likely that some CLABSIs among patients without cancer are included in the 
oncology unit data, and similarly, CLABSIs among patients with cancer may be included in 
the non-oncology unit data. Second, antimicrobial susceptibility data reported to NHSN are 
limited. For example, completeness of antimicrobial susceptibility data varied by organism 
and phenotype. Though data were reported for over 90% of CLABSI for the resistance 
profiles that we have highlighted in our discussion, we may have overestimated the degree of 
resistance for some less common phenotypes (e.g., carbapenem resistance) if most of the 
unreported data were for susceptible organisms. In addition, we did not have data on 
mechanisms of antimicrobial resistance or phenotypic testing beyond an interpreted 
susceptibility result. We do not, for example, receive reports of ESBL production. Third, our 
data are limited to nosocomial CLABSIs. Although central line use is high in oncology units 
[38], resistance patterns for community onset or non-CLABSI infections might differ from 
the hospital-associated and central line-associated infections described here. Fourth, because 
the composition of oncology locations reporting data to NHSN differs from year to year, 
comparing results from one time period to another could be confounded if, for example, 
oncology locations with higher prevalence of fluoroquinolone resistance preferentially 
enrolled in NHSN in later years.
A significant strength of this analysis is that it represents the largest set of data from the 
United States on pathogens and antimicrobial resistance in oncology. Data from multiple 
hospitals illustrates overall increases in antimicrobial resistance compared to prior reports as 
well as likely increased fluoroquinolone resistance during 2009–2012. Reassessment of 
effectiveness of antimicrobial prophylaxis and optimal strategies for antimicrobial treatment 
may be needed in light of these trends.
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Figure 1. 
Incidence rates of central line-associated bloodstream infections (CLABSIs) from selected 
drug-resistant organisms reported to the National Healthcare Safety Network (NHSN) from 
oncology and non-oncology locations.
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Table 1
Characteristics of hospitals and inpatient locations reporting central line-associated bloodstream infection 
(CLABSI) data from inpatient oncology units
Hospital type N (%) (total=183 hospitals)
General hospital 172 (94.0)
Oncology hospital 10 (5.5)
Women’s hospital 1 (0.5)
Inpatient location type N (%) (total=299 inpatient locations)
General hematology/oncology 215 (71.9)
Hematopoietic stem cell transplant 72 (24.1)
Solid tumor oncology ward 6 (2.0)
Leukemia/lymphoma ward 3 (1.0)
Othera 3 (1.0)
a
Includes oncology step-down, leukemia ward, and oncology critical care units
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